Articles

Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study.

Department of Pediatric Hematology and Immunology, Robert Debré University Hospital, AP-HP and University de Paris, Paris, France; Université de Paris, Institut Necker-Enfants Malades (INEM), Institut national de la santé et de la recherche médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris
Pediatric Oncology and Hematology Department, University Hospital of Nancy (CHRU Nancy), Nancy
Service de Biostatistique et d'Epidémiologie, Gustave Roussy Cancer Campus, INSERM U1018, CESP, Université Paris-Sud, Université Paris-Saclay, Villejuif
Department of Biopathology, Morphology Unit, Gustave Roussy, Université Paris Saclay, Villejuif
Pediatric hematology and oncology department, University Hospital of Nantes, Nantes
Department of Biopathology, Morphology Unit, Gustave Roussy, Université Paris Saclay, Villejuif
Department of Pediatric Oncology and Haematology, University Hospital of Bordeaux, Bordeaux
Institut d'Hématologie et d'Oncologie Pédiatrique, Hospices Civils de Lyon, Lyon
Department of Pediatric Oncology and Haematology, University Hospital of Montpellier, Montpellier
Université de Paris, Institut Necker-Enfants Malades (INEM), Institut national de la santé et de la recherche médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris
SIREDO Oncology Center, Institut Curie, PSL Research University, Paris
Pediatric Hematology Oncology Department, University Hospital of Strasbourg, Strasbourg, France and INSERM UMR_S 1109
Departments of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif
Université de Paris, Institut Necker-Enfants Malades (INEM), Institut national de la santé et de la recherche médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris, France; Pediatric Hematology Oncology Department, Sorbonne Université/Trousseau Hospital, APHP, Paris
Departments of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif
Departments of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; INSERM Unité 1015
Haematologica Early view Mar 3, 2022 https://doi.org/10.3324/haematol.2021.280257